17. Trade and other receivables and other current assets

Notes to the consolidated financial statements

 

31 December

(thousands of €)

2019

2018

Trade receivables

39,603

9,206

Prepayments

292

142

Other receivables

14,114

9,261

Trade and other receivables

54,009

18,609

Inventories

255

276

Accrued income

4,443

3,863

Deferred charges

4,439

4,104

Other current assets

9,138

8,244

Total trade and other receivables & other current assets

63,147

26,852

Trade and other receivables increased due to the outstanding receivable as at 31 December 2019 of €17.8 million ($20 million) on Gilead related to a milestone for NDA filing in the United States related to filgotinib and the 50% cost reimbursement for GLPG1690 (€13.4 million) invoiced to Gilead under the cost sharing mechanism.

We consider that the carrying amount of trade and other receivables approximates their fair value.

The other current assets mainly included accrued income from subsidy projects and deferred charges.

On 31 December 2019, we did not have any provision for expected credit losses.